AstraZeneca Patent Appeal Rejected By India

An appeal by Britain's AstraZeneca against a decision to deny patent protection to a cancer-fighting drug in a new setback for global drug firms in the Indian market was rejected by an Indian panel.

The case stems from 2007 when the Indian patent office refused to grant protection to AstraZeneca's Gefitinib, which is used to treat lung cancer, because the drug had "known prior use" and could not be considered an invention.

Patent Ductus Arteriosus
Patent Ductus Arteriosus is a congenital defect of the heart where the fetal passage between pulmonary artery and aorta remains open and causes excess pulmonary blood flow.

The Intellectual Property Appellate Board dismissed the company's appeal against the ruling late Tuesday.

The decision comes with Britain's second largest drugmaker battling sharply falling profits and the loss of patent protection on several of its biggest-selling drugs.

The setback for AstraZeneca, which could not be immediately reached for comment, was the latest to be suffered by a global drug conpany.

Scientists Receive Patent for Development of "combination" Proteins to Produce Vaccines for Lyme Disease
UPTON -- Scientists belonging to the U.S. Department of Energy's Brookhaven National Laboratory and collaborators at Stony Brook University have been granted the U.S. Patent Number 7,179,448

Earlier this year, an Indian ruling allowed a local firm to produce a vastly cheaper copy of German pharmaceutical giant Bayer's patented drug Nexavar for liver and kidney cancer.

Medical charities have expressed concern that compliance with WTO rules could reduce the country's role as a supplier of low-cost medicines. India is the world's leading exporter and manufacturer of non-branded medicines.

Yoga Should Not Be Patented: Ramdev
Stressing that yoga was a centuries-old Indian tradition, popular yoga guru Swami Ramdev urged the government and yoga organizations to prevent it from being patented overseas.

Western firms -- looking to countries such as India for sales growth -- have voiced criticism of brand protection in India.

India has some of the toughest criteria for drug companies to obtain patents, said D.G. Shah, secretary general of the Indian Pharmaceutical Alliance, an industry body.

POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
Poly Medicure Ltd today said it has applied for eight new patents and two USFDA approvals for its new range of safety syringes and safe blood collection holders.

"These rulings show (foreign) companies need to take into account that India will not permit tweaking of formulations for getting a patent. If they had those expectations, they were unrealistic," Shah told AFP recently.

Source-AFP